MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a new research collaboration with Hanmi Pharmaceutical, a prominent biopharmaceutical company in Korea. The partnership aims to identify cancer biomarkers for one of Hanmi’s clinical programs using MEDiC’s…
Eli Lilly and Company (NYSE: LLY) announced a significant $4.5 billion investment to establish the Lilly Medicine Foundry, a state-of-the-art facility for advanced manufacturing and drug development. This innovative center will enable Lilly to explore new methods for medicine production…
The global antibody drug market was valued at $218.6 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 11.2%, reaching $412.1 billion by 2029. This growth is fueled by an increase in product…
Phare Bio, in collaboration with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, has secured up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), part of the U.S.…
Takeda (TOKYO:4502/NYSE: TAK) has announced a commitment of JPY 4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners. This investment is part of Takeda’s ongoing efforts to bolster health system resilience in low- and…
Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma, based…
Chugai Pharmaceutical Co., Ltd. [Head Office: Tokyo, President and CEO: Osamu Okuda] and LTL Pharma Co., Ltd. [Head Office: Tokyo, President and Representative Director: Tetsuo Ito] have announced an agreement under which Chugai will transfer its Japanese business related to…
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced key leadership changes in its research and development and business development teams. Effective September 30, Greg Friberg, M.D., will join the company as Executive Vice President and Chief Research & Development Officer, succeeding…
WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) providing comprehensive solutions for biologics discovery, development, and manufacturing, has announced its unaudited interim results for the first…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has announced the adoption of a limited-duration stockholder rights plan. This plan is set to expire on August 15, 2025. The…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, today announced the granting of inducement equity awards to five newly hired…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have undergone two or more prior treatments. The approval by the…